» Articles » PMID: 38003581

In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Nov 25
PMID 38003581
Authors
Affiliations
Soon will be listed here.
Abstract

The spike (S) protein of SARS-CoV-2 is a molecular target of great interest for developing drug therapies against COVID-19 because S is responsible for the interaction of the virus with the host cell receptor. Currently, there is no outpatient safety treatment for COVID-19 disease. Furthermore, we consider it of worthy importance to evaluate experimentally the possible interaction of drugs (approved by the Food and Drug Administration) and the S, considering some previously in silico and clinical use. Then, the objective of this study was to demonstrate the in vitro interaction of ivermectin with S. The equilibrium dialysis technique with UV-Vis was performed to obtain the affinity and dissociation constants. In addition, the Drug Affinity Responsive Target Stability (DARTS) technique was used to demonstrate the in vitro interaction of S with ivermectin. The results indicate the interaction between ivermectin and the S with an association and dissociation constant of Ka = 1.22 µM and Kd = 0.81 µM, respectively. The interaction was demonstrated in ratios of 1:50 pmol and 1:100 pmol (S: ivermectin) by the DARTS technique. The results obtained with these two different techniques demonstrate an interaction between S and ivermectin previously explored in silico, suggesting its clinical uses to stop the viral spread among susceptible human hosts.

Citing Articles

Design, Synthesis and Biological Exploration of Novel -(9-Ethyl-9-Carbazol-3-yl)Acetamide-Linked Benzofuran-1,2,4-Triazoles as Anti-SARS-CoV-2 Agents: Combined Wet/Dry Approach Targeting Main Protease (M), Spike Glycoprotein and RdRp.

Zahoor A, Munawar S, Ahmad S, Iram F, Anjum M, Khan S Int J Mol Sci. 2024; 25(23).

PMID: 39684420 PMC: 11641759. DOI: 10.3390/ijms252312708.

References
1.
Mathachan S, Sardana K, Khurana A . Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatol Online J. 2021; 12(4):500-514. PMC: 8354388. DOI: 10.4103/idoj.idoj_298_21. View

2.
Malone B, Campbell E . Molnupiravir: coding for catastrophe. Nat Struct Mol Biol. 2021; 28(9):706-708. DOI: 10.1038/s41594-021-00657-8. View

3.
Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

4.
Huang Y, Yang C, Xu X, Xu W, Liu S . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-1149. PMC: 7396720. DOI: 10.1038/s41401-020-0485-4. View

5.
Kong K, Chang Y, Qiao H, Zhao C, Chen X, Rong K . Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis. J Transl Med. 2022; 20(1):549. PMC: 9701426. DOI: 10.1186/s12967-022-03770-4. View